New Horizon Health on Nov. 25 announced that their flagship product, ColoClear, has been approved by the National Medical Products Administration for the screening of Colorectal Cancer (CRC) and precancerous lesion.
New Horizon Health on Nov. 25 announced that their flagship product, ColoClear, has been approved by the National Medical Products Administration for the screening of Colorectal Cancer (CRC) and precancerous lesion.
China’s colorectal cancer screening leader, New Horizon Health announced the closing of a $30 million Series E financing round.